ChloraPrep 1.5 mL applicator
ChloraPrep 1.5 mL applicator
ChloraPrep 1.5 mL applicator

ChloraPrep™ 1.5 mL applicator

Clear Catalogue No: MRB561

Review more than 30 clinical studies and evidence-based guidelines supporting pre-operative skin preparation in this procedure range.

Use for medical procedures including:

  • Blood culture collection
  • Peripheral cannulation
  • Peripheral arterial line cannulation
  • Simple Biopsy
  • Routine Venipunctures
  • Dialysis fistula/graft site cleansing
  • Suitable for patients with delicate skin
  • Rapid-acting: Rapidly kills a broad spectrum of skin-dwelling microorganisms 1, 2
  • Persistent: Maintains antimicrobial activity for at least 48 hours 1 , 3
  • Broad spectrum: Effective against gram-positive and gram-negative bacteria including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), Clostridium difficile, Acinetobacter, and most viruses and fungi 2 , 4 , 5
  • Active in protein-rich biomaterials: Remains active in the presence of blood, serum, and other protein-rich biomaterials 2 , 4
  • Aseptic technique: Sterile, single-use applicator design eliminates direct hand-to-patient contact, helping to reduce cross-contamination 9
  • Gentle friction: Applied in a gentle back and forth motion, the sponge head helps the solution to penetrate the first five cell layers of the epidermis where 80% of microorganisms reside 7
  • Precise application: Triangular head allows precise prepping around catheters
  • Glass ampoule: Ensures a sterile solution is applied to the patients skin upon activation 9
  • 25 sterile applicators per carton
  • Three-year shelf life
  • Latex-free
  • Approximate coverage area 10cm x 13cm
  • Does not contain DEHP

Related Products


ChloraPrep™ and neuraxial procedures

Our response to the AAGBI's safety guidelines.

Learn More

Always Read the Label

SmPC & PIL information

Find Out More

Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.

References
  1. Analyses comparing the antimicrobial activity and safety of current antiseptic agents: A review, Hibbard JS, J Infus Nurs 2005; 28: 194-207
  2. Current approaches for the prevention of surgical site infections, Florman S, Nichols RL, Am J Infect Dis 2007; 3: 51-61
  3. Comparison of ChloraPrep™ and Betadine® as preoperative skin preparation antiseptics, Garcia R, Hibbard JS, Mulberry G et al, Abstracts of the Infectious Disease Society of America 40th Annual Meeting 2002: Abs 418
  4. Skin antisepsis: past, present, and future, Crosby CT, Mares AK, J Vasc Access Devices 2001; Spring: 26-31
  5. Data on file, BD
  6. Microbial Ecology of Human Skin in Health and Disease, Fredericks DN, J Invest Dermatol Symp Proc 2001; 6: 167-9
  7. Effect of topical antimicrobial treatment on aerobic bacteria in the stratum corneum of human skin, Hendley JO, Ashe KM, Antimicrob Agents, Chemother 1991; 35: 627-31
  8. Chlorhexidine: Expanding the armamentarium for infection control and prevention, Milstone AM, Passaretti CL, Perl TM, CID 2008; 46: 274-80
  9. Evaluation of donor arm disinfection techniques, McDonald CP, Lowe P, Roy A, Vox Sanguinis 2001; 80: 135-41
  10. The management and control of hospital acquired infection in acute NHS trusts in England, National Audit Office, February 2000
  11. The socioeconomic burden of hospital acquired infection, Plowman R, Graves N, Griffin M et al, www.dh.gov.uk
  12. The cost-effectiveness of 2% chlorhexidine gluconate in 70% isopropyl alcohol in prevention of central venous access device-related infections in patients admitted to ITU, York N, Hartley-Jones c, Hutchinson J et al, Poster presented at 37th Annual Infection Control Conference, UK, September
  13. Reducing blood-culture contamination rates by the use of a 2% chlorhexidine solution applicator in acute admission units, Madeo M, Barlow G, Hosp Infect 2008; 69: 307-9
  14. Efficacy of surgical preparation solutions in foot and ankle surgery, Ostrander RV, Botte MJ, Brage ME, J Bone Joint Surg Am 2005; 87: 980-5
  15. Prospective, randomised clinical trial to compare the efficacy of two 70% (v/v) isopropyl alcohol (IPA) solutions containing either 0.5% (w/v) or 2% (w/v) chlorhexidine gluconate (CHG) for skin antisepsis during coronary artery bypass grafting (CABG), Casey AL, Itrakjy AS, Harbun C et al, Poster presented at European Congress of Clinical Microbiology and Infection Diseases (ECCMID), Spain, April 2008

2000WS-UK-EN-00671

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.